| Identification | Back Directory | [Name]
NO-1886 | [CAS]
133208-93-2 | [Synonyms]
OPF 009
NO-1886
ibrolipim
Ibrolipim NO-1886
Lipoprotein Lipase Activator
Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate
4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide
N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide
Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate, Ibrolipim, OPF 009
Phosphonic acid, [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-, diethyl ester | [Molecular Formula]
C19H20BrN2O4P | [MDL Number]
MFCD00897807 | [MOL File]
133208-93-2.mol | [Molecular Weight]
451.25 |
| Chemical Properties | Back Directory | [Melting point ]
160.5-162.1 °C | [Boiling point ]
512.5±50.0 °C(Predicted) | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: ≥20mg/mL | [form ]
powder | [pka]
11.51±0.70(Predicted) | [color ]
off-white to pale yellow | [InChI]
1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23) | [InChIKey]
KPRTURMJVWXURQ-UHFFFAOYSA-N | [SMILES]
CCOP(=O)(Cc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C#N)OCC |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS06 | [Signal word ]
Danger | [Hazard statements ]
H301 | [Precautionary statements ]
P301+P310 | [Hazard Codes ]
Xi,T | [Risk Statements ]
36/37/38-25 | [Safety Statements ]
26-36-45 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Acute Tox. 3 Oral |
| Hazard Information | Back Directory | [Uses]
Antiatherogenic; antiobesity;
antidyslipidemia; anticachexia; and antidiabetes/syndrome. | [Biological Activity]
Lipoprotein lipase activator. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Long-term administration of NO-1886 protects against the development of experimental atherosclerosis in animals. | [in vivo]
Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue[2]. | Animal Model: | Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment[2] | | Dosage: | 100 mg/kg | | Administration: | Oral administration; daily; for 8 weeks | | Result: | Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.
|
|
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|